Hims(US:HIMS) GlobeNewswire News Room·2025-07-20 15:07Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of securities law violations related to misleading statements and the promotion of unsafe products [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [5][6]. Group 2: Impact on Stock Price - Following Novo Nordisk's announcement of ending its partnership with Hims due to legal violations, Hims' stock price dropped by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [6]. Group 3: Call for Information - Faruqi & Faruqi encourages individuals with information regarding Hims' conduct, including whistleblowers and former employees, to come forward [8].